Enterprise Value

-8.679M

Cash

669.3M

Avg Qtr Burn

-50.99M

Short % of Float

10.07%

Insider Ownership

11.04%

Institutional Own.

81.57%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Latozinemab (AL001) (progranulin) Details
Frontotemporal dementia with a granulin mutation, Dementia

Phase 3

Data readout

AL002 (TREM 2) Details
Alzheimer's disease

Phase 2

Data readout

Latozinemab (AL001) (progranulin) Details
Frontotemporal dementia with C9orf72 mutation, Dementia, Chronic kidney disease, Kidney disease, Amyotrophic lateral sclerosis

Phase 2

Data readout

AL101 (Progranulin) Details
Alzheimer's disease, Parkinson's disease, Neurological disorder

Phase 2

Initiation

AL003 (SIGLEC 3) Details
Alzheimer's disease

Failed

Discontinued